胰岛素样生长因子2型是比胰岛素样生长因子1型更好的生存标志物,在急性不补偿性心力衰竭后的患者中
Agata Bronisz1, Bartosz J Myśliwiec2, Magdalena Hagner-Derengowska3
1Department of Internal Diseases, Allergology, Endocrinology and Gastroenterology, Institute of Medical Sciences, University of Opole, Poland.
Archives of medical science : AMS
|October 23, 2024
概括
较低的胰岛素样生长因子2 (IGF-2) 水平表明心力衰竭 (HF) 更晚期,死亡风险更高. 与IGF-1不同,IGF-2与HF严重程度和生存结果有显著的关联.
科学领域:
- 内分泌学 在内分泌学.
- 心脏病学 心脏病学
- 生物标志物发现发现
背景情况:
- 在心力衰竭 (HF) 中观察到胰岛素样生长因子1 (IGF-1) 水平的降低.
- 尽管有实验室证据表明IGF-2与IGF-1相比具有强大的心肌细胞增殖效应,但IGF-2在HF中的作用尚未得到充分研究.
研究的目的:
- 研究和比较胰岛素样生长因子1 (IGF-1) 和胰岛素样生长因子2 (IGF-2) 度在心力衰竭 (HF) 患者中.
- 评估IGF-1和IGF-2水平与HF恶化 (NYHA类) 和1年生存率之间的关系.
主要方法:
- 七十五名因新的或恶化的HF住院的患者接受了人体测量,实验室测试,心声学和IGF-1/IGF-2水平评估.
- 参与者被分为NYHA II和NYHA III/IV功能类别.
- 在12个月的时间内监测年生存率.
主要成果:
- 在NYHA类,BMI,代谢状况或生存组之间没有发现IGF-1水平的显著差异.
- 在晚期HF (NYHA III/IV) 患者和在一年内死亡的患者中,IGF-2度显著降低.
- 在IGF-2和总胆固醇 (TC) 和低密度脂蛋白 (LDL) 胆固醇水平之间观察到正相关性.
结论:
- 与IGF-1相比,降低IGF-2度是晚期心力衰竭和增加1年死亡风险的更敏感生物标志物.
- 在心力衰竭患者中,IGF-2分泌可能受到胆固醇水平的影响.
相关概念视频
Heart Failure II: Pathophysiology
1
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1
Insulin: Dosing Regimen and Adverse Effects
148
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
148
Glucagon-like Receptor Agonists
301
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
301
Heart Failure IV: Classification and Diagnostic Evaluation
1
Heart failure can be classified in various ways, with the most common classifications based on physical activity limitations, disease progression, severity, and treatment strategies.The Functional Classification of Heart Failure divides patients into four categories based on physical activity limitation due to symptom burden.Class I: Patients in this class have cardiac disease but no physical activity limitations. Ordinary activities like walking, climbing stairs, or routine tasks do not cause...
1
Heart Failure V: Medical Management
1
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
1
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
61
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
61


